Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial

The researchers compared two home-based exercise programmes in people with mild Parkinson's disease:

• Aerobic exercise group: Stationary cycling on a home-trainer, with virtual reality software and real-life videos to create an "exergaming" experience. Participants aimed for 30–45 minutes per session, three times per week, at 60–85% of their maximum heart rate (high-intensity aerobic zone). They received a motivational app and remote supervision from a coach (physical therapist or research assistant) via telephone or video calls.

• Active control group: Stretching exercises done at home, also for 30–45 minutes, three times per week. This group received the same motivational app and remote supervision. The stretching was designed to be non-aerobic (no heart rate elevation) while controlling for attention, social contact, and the general effects of doing a regular home-based activity.

The primary question was: Does home-based aerobic exercise reduce Parkinson's motor symptoms more than a non-aerobic control activity?

• 130 patients with Parkinson's disease (65 per group)
• Age range: 30–75 years (mean age ~60 years)
• Disease severity: Mild (Hoehn and Yahr stage ≤2, meaning symptoms are unilateral or bilateral but without balance impairment)
• Medication: Stable dopaminergic medication for at least 1 month before enrolment, or untreated and not expected to start treatment within the next month
• Activity level: Sedentary at baseline (doing less than recommended aerobic exercise for older adults: vigorous exercise <3 times/week for 20 minutes, or moderate exercise <5 times/week for 30 minutes)
• Excluded: People on beta-blockers or antipsychotics; those with neurological, orthopaedic, or cardiac conditions making exercise unsafe; psychiatric diagnoses in the past year; dementia; no home internet; or unavailable for >10% of the study period
• Setting: Single centre (Radboud University Medical Center, Nijmegen, Netherlands), recruited from outpatient clinic and via social media
• 125 patients (96%) completed the 6-month follow-up assessment (primary analysis population)

The primary outcome was the Movement Disorders Society—Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor section, Part III. This is a clinician-rated scale assessing 33 motor signs (tremor, rigidity, bradykinesia, gait, posture, etc.), with scores ranging from 0 (no impairment) to 132 (severe impairment). A difference of 3.5 points or more was pre-defined as clinically relevant.

Critically, the assessment was done in the "off" state — meaning patients had not taken their dopaminergic medication for at least 12 hours before testing. This is important because it measures the underlying disease severity rather than medication-driven symptom control.

Secondary outcomes included:

• MDS-UPDRS total score (Parts I–III)
• MDS-UPDRS motor score in the "on" state (1 hour after medication)
• Quality of life (Parkinson's Disease Questionnaire-39)
• Cognitive function (various neuropsychological tests)
• Physical fitness (maximal aerobic exercise test)
• Adherence (training logs from the app)
• Adverse events

Design: Single-centre, double-blind, randomised controlled trial (RCT).

Randomisation: Patients were assigned 1:1 to aerobic exercise or stretching using a web-based system with minimisation for sex and medication status (treated vs. untreated) and permuted blocks of varying sizes (unknown to study personnel). This ensures the groups are balanced on key variables that might influence outcomes.

Blinding: This was a double-blind trial. Patients were only aware of the content of their own assigned programme (they did not know what the other group was doing). Assessors who rated the MDS-UPDRS were unaware of group assignments. This is a major strength — without blinding, expectation effects could inflate the apparent benefit of the "active" intervention. However, true double-blinding of exercise interventions is impossible (patients know if they're cycling hard vs. stretching), so the study used a "blinded patient" design where participants knew their own programme but not the comparator.

Duration: 6 months of training (30–45 minutes, 3 times per week), with assessments at baseline and 6 months.

Statistical approach: Primary analysis was intention-to-treat (ITT) — meaning all patients who completed the 6-month follow-up were analysed according to their original group assignment, regardless of whether they actually completed the training programme. This preserves the benefits of randomisation and reflects real-world effectiveness (some people will drop out or not adhere). The primary analysis used ANCOVA adjusting for baseline MDS-UPDRS score, sex, and medication status.

What this design can prove: An RCT with randomisation, blinding of assessors, and an active control group can establish causality — that the aerobic exercise itself (not just attention, social contact, or the routine of doing something) caused the improvement in motor symptoms. The ITT analysis means the results reflect what would happen if you prescribed this programme to a similar population.

What this design cannot prove:

• It cannot prove disease modification (slowing of neurodegeneration) — only a longer trial with imaging or biomarker endpoints could do that
• It cannot tell us whether the effect persists after stopping exercise
• It cannot compare home-based exercise to supervised gym-based exercise (no direct comparison)
• The single-centre design limits generalisability to other healthcare settings or populations
• The "off-state" testing is artificial — most patients spend most of their day in the "on" state

Methodological strengths:

• Active control group (stretching) rather than no-treatment control, which controls for placebo effects of doing any regular activity
• Assessor blinding
• Pre-registered primary outcome and analysis plan
• ITT analysis
• High retention (96% completed follow-up)

Methodological weaknesses:

• Patients could not be blinded to their own intervention (unavoidable in exercise trials)
• Single centre, limiting generalisability
• Relatively mild disease severity (Hoehn & Yahr ≤2) — results may not apply to more advanced Parkinson's
• 20 patients (15%) did not complete their assigned programme, though ITT analysis mitigates this
• The stretching control group actually worsened by 5.6 points on the MDS-UPDRS over 6 months, which is unusual and may reflect natural disease progression or regression to the mean

Primary outcome (MDS-UPDRS motor score, off state at 6 months):

• Aerobic exercise group: mean change of +1.3 points (SE 1.8) — essentially stable over 6 months
• Stretching control group: mean change of +5.6 points (SE 1.9) — worsening by 5.6 points
• Between-group difference: 4.2 points (95% CI 1.6–6.9, p=0.0020) in favour of aerobic exercise
• This exceeded the pre-defined clinically relevant threshold of 3.5 points

Secondary outcomes:

• MDS-UPDRS total score (Parts I–III, off state): between-group difference of 5.7 points (95% CI 1.3–10.0, p=0.011) in favour of aerobic exercise
• MDS-UPDRS motor score (on state): between-group difference of 2.6 points (95% CI 0.0–5.2, p=0.049) — smaller effect when on medication
• Quality of life (PDQ-39): no significant between-group difference (p=0.13)
• Cognitive function: no significant differences between groups
• Physical fitness (VO₂max): aerobic group improved by ~3.5 mL/kg/min more than control (p<0.001), confirming the intervention was indeed aerobic

Adherence:

• Aerobic group: median 84% of prescribed sessions completed (IQR 67–93%)
• Stretching group: median 82% of prescribed sessions completed (IQR 60–93%)
• No significant difference in adherence between groups

Adverse events:

• Potentially related adverse events: 7 (11%) in aerobic group vs. 4 (6%) in control group — mostly musculoskeletal complaints
• Serious adverse events (unrelated): 3 (6%) in aerobic group (vestibular disorder, vasovagal collapse, knee injury during gardening) vs. 4 (7%) in control group (supraventricular tachycardia, hip fracture, fall-related injury, severe dyskinesias)
• No serious adverse events were directly attributed to the exercise intervention

The 4.2-point difference on the MDS-UPDRS motor scale represents a moderate clinical benefit. To put this in context:

• The aerobic exercise group stayed essentially stable over 6 months (worsening by only 1.3 points), while the stretching group worsened by 5.6 points — roughly what you'd expect from 6 months of natural disease progression in mild Parkinson's
• This means aerobic exercise attenuated motor decline by about 4.2 points compared to doing stretching alone
• The effect was larger than the minimal clinically important difference (3.5 points) but smaller than what you'd typically see from dopaminergic medication (which can improve scores by 10–20 points in the on state)
• The effect was more pronounced in the off state (4.2 points) than the on state (2.6 points), suggesting aerobic exercise may be particularly valuable for managing "off" periods when medication wears off
• The effect on physical fitness (VO₂max improvement of ~3.5 mL/kg/min) is roughly equivalent to what you'd expect from 6 months of moderate-to-vigorous aerobic training in a previously sedentary population

Acknowledged by authors:

• Single-centre design limits generalisability
• Relatively mild disease severity (Hoehn & Yahr ≤2) — results may not apply to more advanced Parkinson's
• Patients could not be blinded to their own intervention
• The stretching control group showed unexpected worsening, which could reflect natural progression or regression to the mean
• The 6-month duration cannot assess long-term effects or disease modification
• Off-state testing is artificial and may not reflect everyday function

Additional critical observations:

• No sham control: While stretching is an active control, it's not a true placebo. Patients in the aerobic group knew they were doing "real exercise," which could create expectation effects that inflate the apparent benefit
• Dropout from the programme: 20 patients (15%) did not complete their assigned programme, though they were still included in the ITT analysis. This is actually quite good adherence for a 6-month home exercise programme
• The control group got worse: The 5.6-point worsening in the stretching group is larger than typical 6-month progression in mild Parkinson's (usually ~3–5 points per year). This could mean the stretching group was unlucky, or that stretching somehow worsened symptoms (unlikely), or that the aerobic group's stability is partly due to regression to the mean
• Industry funding: Funded by the Netherlands Organization for Health Research and Development (government funding), so no industry conflicts of interest
• No long-term follow-up: We don't know if the effect persists, diminishes, or grows after 6 months
• No blinding of patients to their own group: While assessors were blinded, patients knew whether they were cycling hard or stretching. This is unavoidable in exercise trials but means placebo effects cannot be fully ruled out
• Single type of exercise: Only cycling was tested — results may not generalise to other forms of aerobic exercise (running, swimming, etc.)

For someone with mild Parkinson's disease (or caring for someone who has it) who wants to run their own n=1 experiment:

What to test

• Intervention: Home-based stationary cycling, 30–45 minutes per session, 3 times per week, at 60–85% of your maximum heart rate (or a perceived exertion of "somewhat hard" to "hard" — about 6–8 on a 0–10 scale)
• Dose: 6 months minimum (the study duration), though you might see changes earlier
• Equipment: A stationary bike or home-trainer. The study used gamified software, but any bike with resistance control will work. A heart rate monitor is strongly recommended to ensure you're in the aerobic zone
• Control: For a proper n=1 test, try 6 weeks of stretching or gentle walking (non-aerobic) first, then switch to cycling. Or alternate 6-week blocks

Minimum meaningful duration

• 3–6 months to see measurable changes in motor symptoms
• The study showed effects at 6 months; shorter periods may show smaller or no effects
• Adherence is critical — you need to actually do the sessions (aim for ≥80% of prescribed sessions)

What to measure

• Primary metric: MDS-UPDRS Part III (motor examination) — but this requires a trained assessor. A reasonable proxy is the UPDRS Part II (motor experiences of daily living, self-reported) or a simple timed 10-metre walk test and timed up-and-go test
• Secondary metrics:
  • Resting heart rate and heart rate during a standard submaximal exercise (e.g., 5 minutes at a fixed resistance on your bike)
  • Subjective "off" time per day (hours when medication isn't working well)
  • Quality of life (PDQ-39 or a simple 1–10 daily rating)
  • Gait speed and stride length (measure a 10-metre walk, best of 3 trials)
• Adherence: Log every session — date, duration, average heart rate, perceived exertion

Key confounds to control for

• Medication timing: Always test motor symptoms at the same time of day relative to medication (ideally in the "off" state, 12+ hours after last dose, but this is impractical daily — at minimum, test at the same time each day)
• Medication changes: Don't change your Parkinson's medication dose or schedule during the experiment unless medically necessary
• Other exercise: Keep non-study physical activity constant (don't start other new exercise programmes)
• Sleep and stress: Track sleep quality and daily stress (1–10 scale) as these affect Parkinson's symptoms
• Time of day: Test at the same time each day
• Learning effects: If using timed tests, do 3 practice trials before recording baseline

What a positive result would look like

• MDS-UPDRS motor score: A 3.5–4.2 point improvement (or less worsening than expected) over 6 months
• Timed 10-metre walk: Improvement of 0.5–1.0 seconds (faster gait)
• Subjective "off" time: Reduction of 1–2 hours per day
• Physical fitness: Resting heart rate drops by 5–10 bpm; you can maintain a given workload at a lower heart rate
• Daily function: Easier to get out of a chair, turn in bed, or walk without freezing
• Adherence: You're actually doing the sessions (≥80% adherence) — this is a positive result in itself, as the study showed that adherence was achievable at home with remote support

Important caveats

• This study was in mild Parkinson's (Hoe